Lupin Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Lupin Ltd. from all sources in a single place.

Load latest

14 May 2025, 10:24PM

Result

Lupin Ltd - 500257 - Approval Of The Audited Financial Statements For The Quarter And Year …

BSE India

Approval of the Audited Financial Statements for the quarter and year ended March 31, 2025 and recommend the Final Dividend of Rs. 12/- per Equity Share i.e. 600 % of the Face Value of Rs. 2/- each fully paid up for the financial year ended March 31, 2025.

pdf

Lupin Ltd.

14 May 2025, 10:22PM

Result

Lupin Ltd - 500257 - Approval Of The Audited Financial Statements For The Quarter And Year …

BSE India

pdf

Lupin Ltd.

13 May 2025

Lupin shares gain 4% on Tolvaptan Tablets launch in US; details here

Business Standard

Lupin, in a release, said that it holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

13 May 2025

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Launches Tolvaptan Tablets in the U.S. with 180-Day Exclusivity.

pdf

Lupin Ltd.

08 May 2025

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Receives Approval from U.S. FDA for Raltegravir Tablets USP, 600 mg.

pdf

Lupin Ltd.

07 May 2025

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Lupin Lunches Eslicarbazepine Acetate Tablets in the United States.

pdf

Lupin Ltd.

02 May 2025

Company Update

Lupin Ltd - 500257 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

The Company shall be conducting an 'Investors Meet 2025' in Mumbai for Analyst and/or Institutional Investors. The same is scheduled on Thursday, May 15, 2025, at 17.30 hrs (IST).

pdf

Lupin Ltd.

30 Apr 2025

Company Update

Lupin Ltd - 500257 - Updates On Transfer Of Company''s API R&D Division And Over-The-Counter Consumer …

BSE India

Update on transfer of Company''s API R&D Division and Over-the -Counter Consumer Healthcare Business on Slump sale basis.

pdf

Lupin Ltd.

29 Apr 2025

Board Meeting

Lupin Ltd - 500257 - Board Meeting Intimation for Considering And Taking On Record Audited Standalone …

BSE India

Lupin Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2025 ,inter alia, to consider and approve Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025 and recommend dividend, if any.

pdf